Arizona Cannabis: $1.22B in 2025 Revenue, ~Two-Thirds Legal Capture, and the Licensing Cap That Explains the Gap

Arizona launched adult-use cannabis sales on January 22, 2021 — 80 days after the election, the fastest implementation of a voter-approved legalization measure in U.S. history. Four years later, the state generated $1.22 billion in combined medical and adult-use sales in 2025 against a resident consumer base the framework estimates demands roughly $1.8 billion worth of cannabis annually. That two-thirds capture rate is not an accident of demographics or geography. It is the direct consequence of a licensing structure built on an incumbent-protection model — 169 licensed establishments serving 5.62 million adults across 113,990 square miles — and it leaves meaningful growth runway that the state's own tax collection data confirms is still being realized.

Market Overview

Arizona has two distinct policy chapters. Proposition 203, the Arizona Medical Marijuana Act, passed in November 2010 with 50.1% of the vote — the narrowest margin in the dataset. The first licensed medical dispensary opened December 6, 2012. A 2016 adult-use attempt (Proposition 205) failed with 48.7%. Proposition 207, the Smart and Safe Arizona Act, passed in November 2020 with 60% of the vote. Possession became legal November 30, 2020. Adult-use retail sales began January 22, 2021.

Both programs are administered by the Arizona Department of Health Services (ADHS). Tax collection and revenue reporting are handled separately by the Arizona Department of Revenue (ADOR). This two-department structure is a recurring theme in Arizona's data — it is the reason reliable pricing and capture analysis requires cross-referencing sources that were not designed to be used together.

Key metrics:

• $1.22B combined 2025 sales (Medical $186M + Adult-Use $1.03B, per ADOR taxable sales data)
• ~67% estimated legal market capture (two-thirds of estimated resident demand)
• ~169 licensed adult-use establishments, 136 dual-licensed medical dispensaries (ADHS, April 2026)
• 76,322 active medical cardholders (March 2026), down from 299,054 at the January 2021 peak (-74.5%)
• 16% excise tax on adult-use retail + state and local TPT (~6.6%); medical exempt from excise
• Adults 21+: ~5.62 million (Census 2024)
• 13 qualifying medical conditions including chronic pain, cancer, PTSD, HIV/AIDS, Crohn's disease, and seizures
• Home cultivation permitted — up to 6 plants per adult 21+, 12 per household
• Adult-use delivery launched late 2024, creating a new access channel statewide

Flower Pricing and Data Methodology

Arizona is the only state in this dataset where volume data and revenue data are held by separate agencies with no integrated reporting. ADHS publishes monthly medical program reports showing pounds and ounces sold by product category. ADOR publishes taxable sales by channel (medical and adult-use) without volume data. To derive an implied price per gram requires cross-referencing both sources — and that cross-referencing is only clean for the medical channel, because ADHS's volume data covers the medical program only.

The one reliable data point in this analysis: the implied average price across all medical products in July 2021 was $12.97 per gram — derived by dividing ADOR's $70.5M in medical taxable sales against the 5.44 million grams of medical product recorded by ADHS for that month. This is the earliest month for which both datasets are simultaneously available, and it predates meaningful adult-use price competition.

By March 2026, the medical channel implies $6–10 per gram — a range, not a point estimate, because the tax rate applicable to the Medical-203 collections figure in the ADOR data is not definitively knowable from the public record.

For the adult-use channel, which now accounts for 85% of combined revenue, no ADHS volume data exists to allow the same cross-referencing. A review of dispensary menus shows wide price dispersion — from premium indoor product at $5-6+ per gram to high-volume budget product well below that. Blended all-products market average is estimated at $6-10 per gram; flower specifically is likely below $6.

Tax Structure

• Adult-use: 16% excise tax on retail sales + state and local Transaction Privilege Tax (~6.6% combined effective); total consumer burden approximately 22%
• Medical: TPT only (~6.6%); exempt from the 16% excise — meaningful economics for high-frequency medical patients
• Prop 207 excise revenue is allocated to community colleges (33%), police and fire departments (31.4%), the state highway fund (25.4%), a justice reinvestment fund (10%), and the Attorney General (0.2%)
• 2025 excise and TPT collections: approximately $248-253M (consistent with 2023–2024 levels)

Arizona's 22% combined burden sits in the middle of the dataset — lower than Illinois, comparable to New Mexico, neither of which it resembles in capture rate. Tax structure is not the constraint.

Total Addressable Market

Arizona's adult population 21+ is approximately 5.62 million (Census 2024). Applying the consumption baseline of 18% participation at 1.0 gram per day:

• 5,620,000 adults 21+
• 1,011,600 estimated regular consumers (18%)
• 369.2 million grams annual resident demand

One validation data point is available from primary sources: Arizona's ADHS medical program data for January 2021 — the last month before adult-use sales began — shows observed consumption of 0.884 grams per day across all 299,054 active cardholders. Below the 1.0 gram-per-day baseline, but not by enough to materially change the analysis — and consistent with a medical population that skews older and includes lower-frequency users. It confirms the framework's 1.0 gram-per-day assumption is not an undercount.

Against $1.218B in 2025 combined taxable sales, the framework implies approximately 67% legal market capture — roughly two-thirds of estimated resident demand flowing through licensed channels (369.2M grams × blended market average estimated at ~$4.90/g (normalized) = ~$1.81B TAM). The remaining third is the growth opportunity. Because normalized prices are lower than Arizona's average, volume is lower that estimated 67% revenue capture.

Revenue Trend

The revenue trajectory carries an important signal. Arizona's combined tax collections declined only about 2% from 2023 to 2024 — and appear stable into 2025 — despite significant price compression during the same period. Colorado and Oregon both experienced steeper revenue declines as their markets reached full capture and volume growth stalled. Arizona's gentle curve means volume is still growing fast enough to nearly offset falling prices — the legal market is still converting illicit-market consumers, not simply selling cheaper product to the same buyers.

Dispensary Density and Licensing Structure

Arizona has 169 adult-use establishments serving approximately 5.62 million adults — a density of 3.0 per 100,000 adults. The comparison to peer markets is striking.

Proposition 207 grandfathered Arizona's 130 existing medical dispensaries into the adult-use market and added 26 social equity licenses — issued in summer 2022, opened in 2023-2024 — for a total of approximately 169 establishments. The cap formula ties the maximum number of licenses to one marijuana establishment per ten licensed pharmacies in the state, meaning the ceiling rises slowly with population growth rather than responding to market demand signals.

Each license is vertically integrated: cultivation, manufacturing, and retail must operate under the same license. This structure is expensive to build and maintain, making new market entry effectively impossible without acquisition — the dominant market entry strategy since 2021. The result is a concentrated incumbent market rather than the fragmented competitive model that drove New Mexico's price collapse and density expansion.

Municipal opt-outs add a further constraint. Cities like Gilbert allow only minimal operations; Scottsdale, Mesa, and Chandler permit existing dispensaries but restrict new entrants. Access deserts exist within metro Phoenix — the state's largest market — not just in rural areas.

Adult-use delivery, launched in late 2024, expands legal market access across 113,990 square miles without requiring new licenses.

The New Mexico comparison is instructive but incomplete. New Mexico's 138% capture rate reflects both its uncapped licensing model and a significant Texas border export premium — Sunland Park and the broader Doña Ana County cluster generated $112M of New Mexico's $567M in 2025 revenue from El Paso-area consumers crossing the state line. Removing the estimated border export leaves New Mexico at roughly 110-115% resident capture. Arizona, without a comparable export market, at 67% is performing meaningfully below that adjusted benchmark — a gap explained by density (3.0 vs 68.2 per 100K) and the licensing model that produced it.

Home Cultivation

Proposition 207 permits home cultivation: up to 6 plants per adult 21+, maximum 12 per household. Arizona's low-desert climate supports outdoor production for a meaningful portion of the year. As in all markets, the economics of personal cultivation rarely favor home grows when retail prices are competitive.

What the CHS Literature Missed

The Arizona Department of Health Services commissioned a systematic literature review of the relationship between marijuana use and cyclical vomiting syndrome from the University of Arizona College of Medicine in 2013. Examining 94 articles — one case-control study, three cohort studies, and 28 case series and case reports — the review found an evidence base dominated by the lowest tier of clinical evidence. The one case-control study (Choung et al., Mayo Clinic) was rated poor quality.

CHS traces to a 2004 Australian case series — the first published report linking chronic marijuana use to cyclical vomiting. The AGA's diagnostic criteria require cannabis use exceeding four times per week for at least one year, vomiting episodes at least three times annually, and symptom resolution only after six or more months of abstinence. That is a specific clinical profile, not a general population exposure.

Arizona has operated a regulated medical cannabis program for over a decade and processed more than 1.5 million patient card transactions. ADHS has published monthly program reports throughout. CHS does not appear in them. The evidence is consistent with the consumption-based analysis showing population-level CHS prevalence at approximately 0.1% — a rate that would produce a clinically manageable number of affected individuals in any given market, not the public health signal that inflated prevalence claims suggest.

The Bottom Line

Arizona chose speed over breadth. The fastest adult-use launch in U.S. history put legal cannabis in front of consumers in January 2021 — but the license structure written into Proposition 207 ensured that the 130 incumbents who built the medical market would also dominate the adult-use market. The result is a $1.22 billion industry in 2025 serving roughly two-thirds of estimated resident demand, with the remaining third structurally inaccessible because the state has 169 retail establishments across 113,990 square miles.

The growth signal is in the tax data. Colorado and Oregon saw steep revenue declines as their markets reached full capture and price compression stopped finding new consumers to convert. Arizona's collections have declined barely 2% year-over-year despite significant price compression — because volume is still growing. The illicit market is still losing customers to licensed retailers. Delivery, launched late 2024, expands the legal market's geographic reach without requiring new licenses.

The licensing cap is the single variable most likely to determine Arizona's trajectory. The pharmacy-based formula allows slow organic expansion. Until it is meaningfully reformed, Arizona's density profile — and the capture rate it produces — will remain structurally constrained.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.